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ging and Defective Healing,
dverse Remodeling, and
lunted Post-Conditioning in
he Reperfused Wounded Heart*
odh I. Jugdutt, MBCHB, MSC, DM, FRCPC,
ACC,†‡ Anwar Jelani, MD†
dmonton, Canada
ptimal healing of the wounded heart is critical for the
reservation of structural and functional integrity of the
umping chambers and for survival with a favorable out-
ome. This is especially important in elderly patients, in
hom myocardial infarction (MI) is prevalent and in whom
efective healing may promote adverse remodeling, thereby
eopardizing outcome.
ealing post-MI. Acute MI triggers a host of biochemi-
al, molecular, and cellular changes that lead to the highly
omplex, dynamic, and concurrent processes of healing,
epair, and remodeling in an attempt to repair structural
amage and preserve left ventricular (LV) function (1).
See pages 1384 and 1393
ealing after MI involves an orchestrated sequence of:
) acute and chronic inflammation; 2) tissue repair with
broblast proliferation, extracellular matrix and collagen
eposition, myofibroblast and scar formation; and 3) struc-
ural and functional remodeling of infarcted and nonin-
arcted myocardium through cardiomyocyte hypertrophy,
ith little regeneration, and some angiogenesis (1). The
ntensity and rate of the healing, reparative, adaptive/
aladaptive remodeling responses and functional outcome
epend to a large extent on infarct size (1,2). Indeed small
nd predominantly subendocardial or non–ST-segment-
levation myocardial infarctions (NSTEMIs) usually heal
ithin 6 weeks in humans, with formation of a firm scar and
reservation of LV function, size, and shape (1). However,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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he Canadian Institutes of Health, Ottawa, Ontario, Canada.evere and extensive injury, as with large and predominantly
ransmural or ST-segment-elevation myocardial infarctions
STEMIs), result in delayed healing over nearly 6 months in
umans, and induce significant adverse regional and global
V remodeling that impacts negatively on outcome and
urvival (1). Optimizing healing after MI therefore deserves
igh priority in cardiovascular research (1,2).
ging and post-MI healing. Aging has become a major
ealth issue and socioeconomic burden worldwide. The
ging population is increasing, and with it, the morbidity
nd mortality that are largely caused by impaired wound
ealing and other defects. Based on growth in the U.S.
etween 2003 and 2004, the Census Bureau predicted an
ncrease in the number of Americans age 65 years and over
etween 2004 and 2050, from 12% (36.3 million) to 21%
86.7 million). Despite improved therapies, nearly 85% of
ll cardiovascular deaths over the last 2 decades occurred in
he 65-and-over age group (3). The average age for a first
I is 66 years in men and 70 years in women (3). Several
tudies have identified age as a strong predictor of adverse
vents after acute coronary syndromes and elderly persons as
eing a high-risk subgroup (4). Nearly 50% of hospital
dmissions for acute MI and 80% who die are age 65 years
nd over (2). The age-related increase in post-MI mortality
s not just due to larger infarcts. Post-MI heart failure is also
ncreasing, and adverse remodeling is more common in
atients age 65 years and over. Most post-STEMI deaths
re caused by LV free wall rupture, and fibrinolytic therapy
ncreases this risk in elderly patients (5). Therapeutic
trategies over the last decade have improved survival mainly
n patients who are younger than 65 years. Because aging is
n important determinant of post-MI healing (Fig. 1) and
ffects most factors that influence healing (Fig. 2), more
etailed studies that target aging and elderly persons are
ustified.
Aging is associated with impaired immunity and comor-
idities that contribute to impaired healing after MI (Figs.
and 2). Aging also impairs the potential of stem cells and
rogenitor cells for myocardial regeneration. Polypharmacy,
hich is also common in elderly patients, raises concerns
egarding interactions and pleiotropic effects that impact
nflammation and infarct collagen during post-MI healing.
everal commonly used drugs impair healing (i.e., anti-
nflammatory agents for arthritis) and collagen synthesis
i.e., angiotensin-converting enzyme inhibitors, angiotensin
I type 1 receptor blockers, aldosterone antagonists, endo-
helin antagonists, and statins) (1,2,6). These drugs may
rolong the time window of vulnerability for adverse LV
emodeling during post-MI healing (1), and the effect may
e more pronounced in elderly persons. Greater caution is
eeded with these drugs during post-MI healing in elderly
ersons. The issue of gender and drug effects, including
ormone therapy, during post-MI healing in elderly men
ersus women also needs to be addressed.
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Editorial Comment April 8, 2008:1399–1403brupt reperfusion and post-MI healing. Coronary
eperfusion in acute MI improves survival and is undisput-
dly the early therapy of choice. Evidence indicates that
arly reperfusion during small and modest STEMI can limit
nfarct size and adverse LV remodeling or even abort
TEMI altogether. However, late reperfusion is associated
ith reperfusion injury, myocardial stunning and persistent
Figure 1 Known and Potential Factors in Healing After Myocard
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin II type 1 rece
otide phosphate; NF-B  nuclear factor -B; NSAID  nonsteroidal antiinflammat
SLPI  secretory leucocyte protease inhibitor; SPARC  secreted protein acidic an
Figure 2 Aging-Related Defects That Influence Post-MI Healing
1  increased, enhanced; 2  decreased, impaired; Ang  angiotensin; CPC 
EPC  endothelial progenitor cell; MMP  matrix metalloproteinase; NO  nitric oV dysfunction, microvascular damage and no-reflow, ex-
ess free radicals, apoptosis and necrosis, enhanced degra-
ation of the extracellular matrix, decreased collagen cross-
inking and tensile strength of infarct scars, enhanced
nflammation, accelerated healing, and persistent LV re-
odeling (1,7–9). Reperfusion has been shown to decrease
nfarct scar size within 6 months in humans with average
farction
ocker; MMP  matrix metalloproteinase; NAD(P)  nicotinamide adenine dinucle-
g; OFR  oxygen free radical; RAAS  renin-angiotensin-aldosterone system;
in cysteine; TIMP  tissue inhibitor of MMP; TGF  transforming growth factor.
c progenitor cell; CSC  cardiac stem cell;
GF  transforming growth factor; TLR  toll-like receptor.ial In
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April 8, 2008:1399–1403 Editorial Commentges between 61 and 69 years (10,11). Elderly patients are at
reater risk after reperfused STEMI (5,9).
In this issue of the Journal, Bujak et al. (12) tested the
ypothesis that aging-related changes in inflammatory me-
iator expression and impaired responsiveness of senescent
ells to growth factors may be responsible for defective
nfarct healing and adverse remodeling after reperfused MI.
hey focused on cellular mechanisms and compared a
omprehensive array of histomorphometric, molecular, and
chocardiographic end points in young (2 months to 3
onths) and senescent (2 years) mice as well as the
esponse of isolated cardiac fibroblasts to transforming
rowth factor-beta (TGF-) stimulation. They convinc-
ngly show 4 defects in older mice during post-MI healing:
) impaired inflammation with decreased and delayed neu-
rophil and macrophage infiltration, reduced cytokine and
hemokine expression, and impaired phagocytosis of dead
ardiomyocytes; 2) impaired healing with decreased myofi-
roblast density and markedly decreased collagen deposition
n the infarct scar; 3) enhanced dilative and hypertrophic
emodeling and more systolic dysfunction; and 4) a blunted
broblast response to TGF-1. Temporally, despite similar
nfarct size, reperfused MI in young mice induced intense
nflammation after 24 h and replacement with granulation
issue within 72 h (consistent with enhanced inflammation
nd accelerated healing after reperfusion), whereas healing
n the older mice was delayed beyond 7 days. Although the
tudy was not powered to address mortality, there was a
rend for more deaths in the old than young mice after
oronary occlusion and reperfusion. The overall findings
ndicated that suppressed inflammation, delayed repair, and
educed infarct collagen in senescent mice lead to adverse
V remodeling, providing compelling arguments for mod-
fying therapy in elderly persons.
Bujak et al. (12) were careful to use a closed-chest snare
odel to avoid the effects of surgery on the inflammatory
ariables. They wisely warn against extrapolation of findings
rom young animals to elderly human patients and against
sing anti-inflammatory therapies in reperfused MI. How-
ver, a third caveat concerns extrapolation of findings in
ice to humans based on at least 3 lines of evidence. First,
he inflammatory response differs between mice and dogs.
ewald et al. (13) showed that infarcts in young mice (1.5
onths to 2 months) show similar rapid inflammatory
nfiltration, clearance of dead cardiomyocytes, and induction
f endothelial adhesion molecules, cytokines, and chemo-
ines as dogs; however, unlike dogs, mice show only
ransient macrophage infiltration and up-regulation of mac-
ophage colony-stimulating factor (M-CSF), no significant
ccumulation of mast cells, no induction of stem cell factor
SCF) that is a growth factor for mast cells, and more
bundant angiogenesis. Second, the response to anti-
nflammatory agents differs between large and small ani-
als. Thus, Timmers et al. (14) showed that inhibition of
yclooxygenase (COX)-2, a cardioprotective protein in
schemia-reperfusion and mediator of pre-conditioning in
a
fice but also proinflammatory, results in impaired healing,
ecreased infarct collagen, and increased LV rupture in pigs.
hird, healing in small animals such as mice (13) and rats
15) is more rapid and remodeling is more severe than in
ogs (13,15) and humans (1), resulting in mature scar after
bout 14 days in mice, 21 days in rats, 36 days to 42 days in
ogs, and 45 days to 180 days in humans (1).
Despite these clinically relevant species-dependent differ-
nces from studies in mice, such as the greater impairment
f mast-cell dependent repair (13), and propensity to LV
upture (14) and the slower healing and remodeling (1) in
arge animals after MI, mice are ideally suited for studies of
ging and healing post-MI. Such studies consistently show
mpaired healing and/or repair, adverse remodeling, and
ecreased survival in older mice (12,16). In fact, Gould et al.
16) suggested that old mice (14 months) might be the
referred model for post-MI congestive heart failure be-
ause they develop less effective repair and adverse remod-
ling with infarct expansion and septal hypertrophy,
hereas young mice (2 months) do not. Of note in that
tudy (16), captopril in the older mice improved survival and
imited hypertrophy (as in humans) but did not limit infarct
emodeling.
Four other points need emphasis. First, the shorter
ifespan of mice (Table 1) make longitudinal studies of
ging feasible, whereas similar studies in large animals are
revented for logistic reasons and prohibitive cost. Second,
o place translational research studies in the clinical context,
rom Table 1, a 2-year-old mouse would be equivalent to a
2-year-old human and a 2-month-old mouse to a 6-year-
ld human. Third, it is also important to note that tempo-
ally, both the march to necrosis and the march to scar
ormation after MI are much abbreviated in mice compared
ith large animals and humans. Fourth, most preclinical
tudies in mice have been performed in young animals and
ost clinical studies in adult rather than elderly humans (9),
lthough first MIs in humans occur in elderly persons.
Bujak et al. (12) do not provide data on antiinflammatory
gents, proof of cause-and-effect between defective healing
nd adverse LV remodeling using genetic models, or the
egional distribution of several pertinent genes (e.g.,
ERCA2, phospholamban, and ANP). Nevertheless, their
nding of suppressed inflammatory and healing responses in
ld mice (12) endorses the need for caution when using
nimal Age, Life Expectancy,d Equivalenc to Hum Years
Table 1 Animal Age, Life Expectancy,and Equivalence to Human Years
Mouse Rat Pig Dog
Life expectancy (yrs) 2 4 10–15 20
Equivalence (1 animal
yr to human yrs)
34–38 30 39 7*
10.5 dog yrs/human yr for the first 2 yrs, and 4 dog yrs/human yr thereafter. Data from
ww.cbsnews.com/stories/2000/05/10/tech/main193799.shtml, www.futurepundit.com/
rchives/002042.html [mouse]; www.ratbehavior.org/RatYears.htm [rat]; www.spfpig.com/data/
00608_Leaflet_E.pdf, www.findarticles.com/p/articles/mi_qn4155/is_20040905/
i _n12557805 [p ig ] ; www.on l ineconvers ion .com/dogyears .h tm [dog] ; www.
rance-property-and-information.com/dog-years-to-human-years-age.htm.
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Editorial Comment April 8, 2008:1399–1403gents with anti-inflammatory effects in elderly patients
fter reperfused MI and supports recent concerns raised by
he American Heart Association about the use of anti-
nflammatory agents after STEMI (17). Finally, the find-
ngs of Bujak et al. (12) have important implications for the
evelopment of post-MI therapy in elderly persons.
radual reperfusion. The rate of reperfusion in animal
odels (after release of ligatures or snares) is more abrupt than
n the human setting (after primary intervention or thrombo-
ytic therapy). Post-conditioning (PC), consisting of brief
pisodes of ischemia-reperfusion applied after sustained isch-
mia and before permanent reperfusion, provides gradual early
eperfusion that is cardioprotective. In contrast to classic
schemic preconditioning, which must be applied before acute
I and therefore is not clinically feasible, PC is an attractive
echnique for reducing infarct size and is clinically applicable
fter STEMI. Indeed, PC has been beneficial during percuta-
eous transluminal coronary angioplasty in human STEMI
atients, with a decrease in creatine kinase infarct size (18,19).
owever, the average age was 58 years in the prospective study
18) and 62 years in the retrospective study (19). Importantly,
hese studies (18,19) provided proof that reperfusion injury
ccurs in humans and PC is clinically feasible. The PC has
een effective in all animals tested except pigs. The mecha-
isms for the PC-induced myocardial salvage include the early
ctivation of classic survival kinase (i.e., the phosphatidylino-
itol-3-kinase– endothelial nitric oxide synthase–Akt;
xtracellular-signal regulated kinase [ERK] 1/2) pathways as
ell as early inhibition of the mitochondrial permeability
ransition pore, oxidants, and inflammation. Akt (also called
kt1 or protein kinase B), originally named after the viral
ncogene in the transforming retrovirus AKT8, is involved in
oth survival and protein synthesis pathways. In fact, PC
ttenuates most triggers of early reperfusion injury (i.e., cardi-
myocyte and vascular endothelial apoptosis and necrosis,
xidants, inflammatory cytokines, neutrophils, apoptotic
egulators).
In this issue of the Journal, Przyklenk et al. (20) provide
dditional insight into the mechanism of aging-related atten-
ation of PC-mediated cardioprotection. Using an isolated
eart model with 30 min ischemia followed by abrupt reper-
usion or PC (3 or 6 cycles of 10-s reperfusion and 10 s
schemia before permanent reperfusion), they nicely show that
C-induced limitation of infarct size seen in adult mice (3 to
 months) is blunted in old mice (20 to 24 months). More
mportantly, they show that this attenuation of cardioprotec-
ion in old mice is associated with similar increase in mitogen-
ctivated protein kinase phosphatase-1 (MKP-1) as in adult
ice but a decrease in ERK 1/2 phosphorylation (rather than
n increase as found in adult mice). Additionally in old mice,
KP inhibition with orthovanadate (PD98059) attenuated
he PC-induced increase in MKP-1, and restored the increase
n ERK and decrease in infarct size. Furthermore, PC did not
lter Akt in the young or old mice and the
hosphatidylinositol-3 kinase inhibitor LY294002 in supple-
entary studies did not block infarct size reduction (nothown). This suggests that the ERK pathway may be the main
urvival pathway in PC. However, loss of PC-induced cardio-
rotection with aging was recently reported in signal trans-
ucer activator of transcription-3–deficient mice (21), suggest-
ng that other signaling mechanisms might be involved in
lderly persons. It is pertinent that as in other PC studies,
rzyklenk et al. (20) did not find incremental benefit on LV
unction compared with abrupt reperfusion. They also relied
n immunoblotting and did not establish cause and effect using
enetic models.
uture directions. There is a need to develop therapeutic
trategies that will optimize healing of the aging heart
ounded by a reperfused STEMI, with or without PC.
ore studies are needed in elderly persons with STEMI,
ith special focus on healing, and should include establish-
ng the potential benefit of PC on long-term LV function,
emodeling, and outcome during healing and beyond.
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